{
    "id": 25744,
    "fullName": "PAK1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PAK1 over exp indicates an over expression of the Pak1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5058,
        "geneSymbol": "PAK1",
        "terms": [
            "PAK1",
            "alpha-PAK",
            "IDDMSSD",
            "p65-PAK",
            "PAKalpha"
        ]
    },
    "variant": "over exp",
    "createDate": "11/15/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9272,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an Iressa (gefitinib) resistant non-small cell lung cancer cell line xenograft model harboring an EGFR mutation and over expressing PAK1 demonstrated restored sensitivity to Iressa (gefitinib) when combined with IPA-3, resulting in almost complete suppression of tumor burden (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 4960,
                "therapyName": "Gefitinib + IPA-3",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9273,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an Iressa (gefitinib) resistant non-small cell lung cancer cell line xenograft model harboring an EGFR mutation and over expressing PAK1 demonstrated restored sensitivity to Iressa (gefitinib) when combined with Obatoclax (GX015-070), resulting in almost complete suppression of tumor burden (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 4961,
                "therapyName": "Gefitinib + Obatoclax",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9245,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung cancer cell line harboring an EGFR mutation and over expressing PAK1 demonstrated resistance to Iressa (gefitinib) in culture (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9271,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an Iressa (gefitinib) resistant non-small cell lung cancer cell line xenograft model harboring an EGFR mutation and over expressing PAK1 demonstrated restored sensitivity to Iressa (gefitinib) when combined with Perifosine, resulting in almost complete suppression of tumor burden (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 4959,
                "therapyName": "Gefitinib + Perifosine",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9270,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an Iressa (gefitinib) resistant non-small cell lung carcinoma cell line harboring an EGFR mutation and over expressing PAK1 demonstrated sensitivity to LY294002, resulting in decreased cell viability and reduced signaling of the PI3K pathway (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26790,
            "profileName": "PAK1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26795,
            "profileName": "EGFR mut PAK1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}